Thermo Fisher Scientific agreed to buy Clario for about $9 billion, acquiring software that captures, manages and analyzes clinical-trial endpoint data. The acquisition complements Thermo Fisher’s earlier CRO assets such as PPD and positions the company to offer integrated services across trial operations and data analytics. Analysts framed the deal as strategic vertical integration to shorten trial cycles and capture higher-value data services.